Celsentri

RSS

maraviroc

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Celsentri. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Celsentri.

For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 22/08/2022

Authorisation details

Product details
Name
Celsentri
Agency product number
EMEA/H/C/000811
Active substance
maraviroc
International non-proprietary name (INN) or common name
maraviroc
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AX09
Publication details
Marketing-authorisation holder
ViiV Healthcare B.V.
Revision
28
Date of issue of marketing authorisation valid throughout the European Union
18/09/2007
Contact address

Van Asch van Wijckstraat 55 H
3811 LP Amersfoort
The Netherlands

Product information

19/08/2022 Celsentri - EMEA/H/C/000811 - IG1531

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating